Cash expected to fund operations into the second half of 2026 Company focused on advancing next-generation anti-cancer ...
Cash expected to fund operations into the second half of 2026Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback